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Leishmania microtubules play an important role not only in cell division, but also in keeping the shape of
the parasite and motility of its free-living stages. Microtubules result from the self-assembly of alpha and
beta tubulins, two phylogenetically conserved and very abundant eukaryotic proteins in kinetoplastids.
The colchicine binding domain has inspired the discovery and development of several drugs currently in
clinical use against parasites. However, this domain is less conserved in kinetoplastids and may be
selectively targeted by new compounds. This report shows the antileishmanial effect of several series of
compounds (53), derived from podophyllotoxin (a natural cyclolignan isolated from rhizomes of Podo-
phyllum spp.) and podophyllic aldehyde, on a transgenic, fluorescence-emitting strain of Leishmania
infantum. These compounds were tested on both promastigotes and amastigote-infected mouse sple-
nocytes, and in mammalian e mouse non-infected splenocytes and liver HepG2 cells e in order to
determine selective indexes of the drugs. Results obtained with podophyllotoxin derivatives showed that
the hydroxyl group at position C-7awas a structural requisite to kill the parasites. On regards podophyllic
aldehyde, derivatives with C9-aldehyde group integrated into a bicyclic heterostructure displayed more
potent antileishmanial effects and were relatively safe for host cells. Docking studies of podophyllotoxin
and podophyllic aldehyde derivatives showed that these compounds share a similar pattern of inter-
action at the colchicine site of Leishmania tubulin, thus pointing to a common mechanism of action.
However, the results obtained suggested that despite tubulin is a remarkable target against leishmani-
asis, there is a poor correlation between inhibition of tubulin polymerization and antileishmanial effect
of many of the compounds tested, fact that points to alternative pathways to kill the parasites.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Visceral leishmaniasis (VL) is a vector-borne zoonotic disease
responsible for one of the most neglected diseases linked to the; VL, Visceral Leishmaniasis;
iRFP, Infra Red Fluorescent
rbalf@unileon.es (R. Bala~na-
Ltd on behalf of Australian Society fpoorest communities of low-income countries. The treatment of
this disease is based on chemotherapy, since potential vaccines
are in preclinical or early clinical stages of development (Beaumier
et al., 2013). Current pharmacopeia against this disease includes
the first line antimony derivatives (SbV), different formulations of
the polyene fungicide amphotericin B (AMB) and the oral alkyl-
phosphocholine miltefosine (Bala~na-Fouce et al., 1998; Monge-
Maillo and Lopez-Velez, 2013). These compounds have many
undesirable side effects that include SbV cardiotoxicity (Sundar
and Chakravarty, 2010), AMB nephrotoxicity (Croft and Olliaro,
2011) and the developmental toxicity of miltefosineor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
J.M. Escudero-Martínez et al. / International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 272e285 273(Bhattacharya et al., 2007). Therefore, the discovery and devel-
opment of new drugs based on validated targets against VL is an
urgent need, especially when Big Pharma companies have waived
funds and efforts in research and development against this
neglected disease.
Microtubule-targeting (antimitotic) drugs include compounds
of diverse structure that can disrupt microtubule function by
interacting with tubulin (Dumontet and Sikic, 1999). Microtubules
are eukaryotic protein structures resulting from the polymerization
of a/b-tubulin heterodimers. Microtubules are responsible for the
formation of the mitotic spindle, cell shape, ciliary and flagellar
motility and intracellular transport (Hawkins et al., 2010). b-
Tubulin is a GTP-hydrolyzing and highly conserved protein that
interacts with a-tubulin, both conforming the basic structural
subunit of microtubules. Microtubules of trypanosomatids have
some unique features. They are constituted by the most abundant
protein in these cells, since they are responsible for the sub-
pellicular corset that conforms their specific shape (Seeback et al.,
1990; Kohl and Gull, 1998). In addition, they are relatively stable
at low temperatures, in contrast to microtubules of many higher
organisms, and they are also resistant to many drugs currently used
in anthelminthic and anticancer therapies (Werbovetz, 2002). One
of these drugs is colchicine, a potent inhibitor of tubulin polymer-
ization in higher eukaryotes (Vindya et al., 2015). In mammals,
colchicine binds to a b-tubulin domain located near the a/b-tubulin
interface, where it prevents tubulin to adopt a straight linear
structure required for further adequate polymerization (Ravelli
et al., 2004). Despite b-tubulin is highly conserved from trypano-
somes to other higher eukaryotic organisms, up to eleven amino
acid substitutions are found in the colchicine-binding site that may
explain the resistance of these parasites to such drug (Luis et al.,
2013). These differences have been pointed as putative targets to
be exploited in the design of new more selective polymerization
inhibitors (Kaur et al., 2014).
Several drugs have been used to target trypanosomatids mi-
crotubules with low activity against mammalian counterparts.
These drugs can act either by inhibiting or promoting tubulin
polymerization. Dinitroaniline herbicides have shown activity
against both Leishmania and Trypanosoma (Chan and Fong, 1990;
Chan et al., 1991, 1993a, 1993b; Traub-Cseko et al., 2001), and
tubulin has been implicated as being the target of these com-
pounds (Chan and Fong, 1990; Chan et al., 1993b; Traub-Cseko
et al., 2001). One interesting natural compound in cancer
chemotherapy is podophyllotoxin (Fig. 1), an antineoplastic and
antiviral cytotoxic cyclolignan isolated from Podophyllum spp.
(Berberidaceae) and several species of other genera and families.
From a mechanistic point of view, it has been demonstrated that
podophyllotoxin and most of its related 40-methoxy congeners act
by inhibiting tubulin polymerization through interaction at theFig. 1. Structures and numbering of positions and rings of podocolchicine-binding site (Ravelli et al., 2004), while another not yet
completely defined apoptosis mechanism has been proposed for
some of those compounds included in other study (Castro et al.,
2010).
This article describes for the first time the evaluation of the
killing effect of several series of semisynthetic podophyllotoxin
derivatives on Leishmania infantum, the aetiological agent
responsible for VL in humans and dogs in the Old World. For this
purpose, an intracellular screening on macrophages isolated from
naturally infected BALB/c mice with an infrared-emitting
L. infantum strain was used. This method has the remarkable
advantage of using host-infected cells under natural conditions,
where splenocytes are still playing a role in the immunological
response (Reguera et al., 2014). Furthermore, we have studied the
potential role played by leishmanial tubulin as putative target of
these compounds.
2. Material and methods
2.1. Chemistry
The chemical structures of the starting compounds podo-
phyllotoxin and podophyllic aldehyde (Fig. 1) and the derivatives
evaluated in this work are compiled in Tables (1e4). Compounds
were prepared according to previous reports (Castro et al., 2004,
2010, 2012; Abad et al., 2012) and to unpublished procedures
(chemical data not shown here). Their structures were respectively
confirmed or assigned by either direct comparison with authentic
samples, or through complete analysis of One- and Two-
Dimensional 1H and 13C nuclear magnetic resonance (1D- and
2D-NMR, respectively), infrared (IR) and mass (MS) spectra for the
new compounds.
2.2. Ethic statement
The animal research described in this manuscript complies with
Spanish Act (RD 53/2013) and European Union Legislation (2010/
63/UE). The protocols used here were approved by the Animal Care
Committee of the University of Leon (Spain), project license num-
ber (PI12/00104).
2.3. Promastigote cultures and in vitro assays
Leishmania infantum BCN150 iRFP (henceforth referred as
L. infantum-iRFP) is a genetically modified strain that constitutively
incorporates the infrared iRFP encoding gen for infrared detection
(Calvo-Alvarez et al., 2012) Promastigotes were cultured in M199
medium supplemented with 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 6.9, 10 mM glutamine,phyllotoxin (2a, left) and podophyllic aldehyde (14, right).
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1640 vitamin mix (Sigma), 10% (v/v) heat-inactivated foetal calf
serum (FCS; Fisher Scientific), and antibiotic cocktail (50 U/mL
penicillin and 50 mg/mL streptomycin) and aliquoted into 96-well
plates, 180 mL per well. Stock solutions of each compound were
prepared in dimethylsulfoxide (DMSO) and stepwise diluted in
M199 media (Sigma). Growing concentrations of each compound
(0.07e300 mM) were added to wells. The final concentration of
DMSO was never higher than 0.1%. 20 mL of each prepared con-
centrationwere added for well. DMSO and AMBdcwere included as
negative and positive controls, respectively. All compounds and
controls were assayed by triplicate.
2.4. Ex vivo splenic explant cultures
To obtain primary infected splenic explants, BALB/c mice were
inoculated intraperitoneally with 108 L. infantum-iRFP metacyclic
promastigotes. Briefly, infective promastigotes were isolated from
stationary-phase culture by negative selection with peanut agglu-
tinin (Sigma) (Sacks and Perkins, 1984). Five weeks post-infection,
mice were slaughtered and spleens were aseptically dissected,
washed in cold phosphate-buffered saline (PBS), and placed in petri
dishes. Small pieces were obtained by using a scalpel. In order to
obtain a single-cell suspension, tissue was incubated with 5 mL of
2 mg/mL collagenase D (Roche) prepared in buffer (10 mM HEPES
[pH 7.4], 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1.8 mM CaCl2)
for 20 min. A cell suspension containing traces of spleen mass was
gently passed through a 100-mm cell strainer to remove tissue
fragments (Bala~na-Fouce et al., 2012). Splenocytes were washed
twice with PBS by centrifugation (500  g for 7 min at 4 C) and
resuspended in RPMI medium supplemented with 10% FCS, 1 mM
sodium pyruvate, 1  RPMI vitamins, 10 mM HEPES, and 50 U/mL
penicillin and 50 mg/mL streptomycin at 37 C under a 5% CO2 at-
mosphere. Cells were counted and diluted at different cell densities.
Cells were seeded until confluence, and different concentrations of
the studied compounds were administered to the explants for 48 h.
The viability of infecting amastigotes was assessed by recording the
fluorescence emission of infected splenocytes at 708 nm in an
Odyssey (Li-Cor) infrared imaging system.
2.5. Cytotoxicity assay and selectivity index (SI) determination
Cytotoxicity of each compound was assessed on uninfected
ex vivo explants and on the human hepatocarcinoma cell HepG2
line (ATCC HB-8065). HepG2 cells were cultured in The Glutmax
Dulbecco's Modified Eagle's Medium (DMEM, Gibco), supple-
mented with 10% (v/v) FCS, 100 mg/mL penicillin and 100 mg/mL
streptomycin. Both strains were seeded in 96-well plates in the
presence of different concentrations of the assayed compound for
48 h at 37 C. Viability of the cultures was determined using the
Alamar Blue staining method, according to manufacturer's rec-
ommendations (Invitrogen).
Selectivity Indexes (SI) for the compounds were determined as
the ratio between the CC50 values for non-infected mouse spleno-
cytes (SIs) or CC50 values for HepG2 (SIh) and the EC50 values for
amastigotes in infected splenocytes.
2.6. Purification of leishmanial tubulin
L. infantum (wild type strain) tubulin was isolated according to
(Yakovich et al., 2006). Two-liter flasks of L. infantum promastigotes
were grown up to a cell density of approximately 1  109 cells/mL.
Cells were harvested and washed twice in PBS and resuspended in
0.1 mM piperazine N, N’-bis(2-ethanesulfonic acid) (PIPES) buffer
(pH 6.9), containing 1 mM glycol ether diamine tetraacetic acid(EGTA) and 1 mMMgCl2. The resulting suspensions were sonicated
on ice (5 cycles 5 pulses of 30 s each), and then were centrifuged in
a Beckman Optima XL using a 70.1 Ti rotor at 40 000  g for
45 min at 4 C. The protein suspension was loaded onto a DEAE
Sepharose (fast flow) and eluted with the same buffer containing
0.3 M KCl/0.75 M l-glutamate. The purity of the leishmanial tubulin
suspension was more than 90% and was analyzed by poly-
acrylamide gel electrophoresis in denaturing conditions (SDS-
PAGE).
2.7. Tubulin polymerization assays
Reactions of tubulin-assembly/depolymerization by drugs were
carried out in 384-wells black microplates with optical bottom
(Thermo) in a final volume of 40 mL. Each reaction contained 1.2mg/
mL freshly isolated Leishmania tubulin, 0.1 mM PIPES (pH 6.9),
1 mM EGTA and 1 mMMgCl2, final concentrations, without or with
the assayed compounds or colchicine as reference. The compounds
were added to the microplate maintained at 4 C. The assembly
reaction was initiated by adding 2 mL of 40 mM GTP (2 mM final
concentration). Variation of the absorbance at 340 nm was recor-
ded in a Synergy HT microplate reader up to 45 min at 37 C. IC50
values are reported as the mean ± SD of at least three different
experiments assayed by duplicate.
2.8. Molecular modelling and structural analysis
The homology model of L. infantum b-tubulin (GenBank
LinJ.08.1280) was generated using the crystallographic structure of
the bovine protein (PDB 4O2B) as template (Prota et al., 2014). An
initial model was obtained with the SWISS-MODEL modelling
server (Schwede et al., 2003) and the tools Modeller 9.13 (Sali and
Blundell, 1993; Fiser et al., 2000; Marti-Remon et al., 2000). Mo-
lecular figures were prepared using VMD (Humphrey et al., 1996)
and UCSF Chimera (Pettersen et al., 2004; Yang et al., 2012). The
validation of the final model was carried out with MEAN (Benkert
et al., 2008, 2009, 2011) and PROCHECK programs (Laskowski
et al., 1993).
Molecular docking studies were carried out to identify the
binding affinities between the inhibitors and tubulins. Docking
calculations were performed using the AutoDock 4.2 software
(Morris et al., 2009). A grid box of 66  44  66 points with a grid
spacing of 0.375 Å and centered at the amino acid in position 200
was used to calculate the atom types needed for the calculations.
The best binding mode of each molecule was selected based on the
lowest binding free energy and the largest cluster. Ligand in-
teractions with tubulin models of Bos taurus and Leishmania sp.
were made with MAESTRO 10.2 software (Schr€odinger, LLC, New




3.1. Activity of podophyllotoxin derivatives against L. infantum
A set of 53 compounds with varied substitution arrangements
on the fused tetracyclic core of podophyllotoxin or the tricyclic core
of podophyllic aldehyde (Fig. 1) were tested in vitro for their ability
to kill both stages of L. infantum. Results from the antileishmanial
tests revealed that some of these compounds killed both promas-
tigotes and splenic amastigotes at low micromolar EC50 level.
Values of antiparasitic activity obtained with podophyllotoxin de-
rivatives were generally better on intracellular amastigotes than on
free-living promastigotes (Table 1). However, this result could be
Table 1
Structures and bioactivity results for podophyllotoxin derivatives. Antileishmanial effects (EC50 ± SD) on promastigotes and amastigote-infected splenocytes (amastigotes) of
L. infantum. Cytotoxicity effects (CC50 ± SD) on murine splenocytes and human HepG2 hepatocytes. Inhibition effects (IC50 ± SD) on leishmanial tubulin polymerization.
Comp. R EC50 (mM) CC50 (mM) CC50 (mM) IC50 (mM)
L. infantum promastigotes L. infantum amastigotes Murine Splenocytes SIS Human HepG2 SIh Leishmania tubulin
1 H >100 >100 98.6 ± 3.1 <1.0 >100 un 7.9 ± 0.3
2a >100 13.4 ± 0.8 >100 >7.4 0.7 ± 0.0 0.1 0.3 ± 0.0
2b >100 >100 >100 <1.0 30.6 ± 2.1 <0.3 2.7 ± 0.1
3 >100 >100 60.6 ± 7.7 <0.6 10.3 ± 0.9 <0.1 4.0 ± 0.2
4 23.2 ± 0.5 >100 0.4 ± 0.0 <0.01 >100 un 3.5 ± 0.8
5a 13.8 ± 0.2 15.6 ± 0.1 16.4 ± 1.7 1.1 >100 >6.4 1.1 ± 0.1
5b 24.9 ± 0.4 6.7 ± 0.3 18.0 ± 1.8 2.7 >100 > 14.9 5.0 ± 0.3
6a >100 7.4 ± 0.4 6.4 ± 0.8 0.9 33.1 ± 2.1 4.5 3.4 ± 0.3
6b 14.5 ± 0.3 9.3 ± 0.4 1.7 ± 0.2 0.2 >100 > 10.8 4.1 ± 0.1
7a 10.4 ± 0.6 44.3 ± 3.2 6.8 ± 0.2 0.2 >100 >2.3 7.7 ± 0.6
8 61.2 ± 7.8 >100 55.5 ± 3.3 <0.6 76.0 ± 1.5 <0.8 8.0 ± 1.4
9 >100 53.7 ± 5.2 57.1 ± 2.5 1.1 >100 >1.9 6.9 ± 0.5
10 >100 46.3 ± 8.8 15.9 ± 0.1 0.3 >100 >2.2 4.4 ± 0.9
11 >100 79.1 ± 5.3 38.0 ± 2.5 0.5 >100 >1.3 8.8 ± 4.5
12 66.4 ± 6.8 >100 11.4 ± 2.0 0.1 >100 un 3.4 ± 0.5
13 >100 5.9 ± 1.1 4.3 ± 0.6 0.7 >100 > 17.1 5.5 ± 0.0
Miltefosine 5.9 ± 1.4 2.40 ± 0.2 64.7 ± 7.0 26.9 50.4 ± 4.3 21 nt
AMBdc 0.8 ± 0.1 0.3 ± 0.0 >20 >62.5 nt un nt
a ~1:1 mixture of C-7a and C-7b epimers. SIS: Selectivity Index (mouse splenocytes); SIh: Selectivity Index (human HepG2); nt: not tested; un: undefined. Significant values
(EC50: <10 mM, SI: > 10, and IC50: <1 mM) are bolded for comparison purposes.
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compounds and their cytotoxicity for uninfected host
macrophages.
We examined the EC50 values found for podophyllotoxins with
antileishmanial effect against amastigotes in the context ofmolecular structure-activity correlation. An initial comparison
revealed that while the unsubstituted core molecule deoxy-
podophyllotoxin (1) was essentially inactive (EC50 > 100 mM), the
presence of a single hydroxyl (OH) substituent at C-7a in podo-
phyllotoxin (2a) conferred a significant antileishmanial activity
J.M. Escudero-Martínez et al. / International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 272e285276(EC50: 13.4 mM). Similarly, the presence of small aliphatic alkyl or
alkenyl substituents at position C-7 (compounds 4e6b), did in-
crease substantially the killing potency of the parental compound 1
on both Leishmania and mouse cells, while lesser or minimum
enhancements were observed after the introduction of larger
alkenyl (7, 8), or hydroxyalkyl (9, 10), or alkoxy/cycloalkoxy (11, 12)
substituents. Very interestingly, the presence of a 7apyranylglycol
fragment in compound 13, led to the most potent antiamastigote
molecule of this series. Though the antileishmanial potency of
several compounds of this series resulted in the range of the clin-
ically used antimonial drugs and miltefosine (Seifert et al., 2003;Table 2
Structures and bioactivity results for podophyllic aldehyde derivatives with changes a
amastigote-infected splenocytes (amastigotes) of L. infantum. Cytotoxicity effects (CC50
(IC50 ± SD) on leishmanial tubulin polymerization.
Comp. R EC50 (mM)
L. infantum promastigotes L. infantum amastig
14 89.5 ± 4.3 9.3 ± 0.5
15 57.0 ± 4.2 29.8 ± 1.6
16 35.2 ± 7.5 nt
17 25.7 ± 3.6 18.1 ± 0.1
18 64.8 ± 4.9 4.3 ± 0.1
19 >100 56.3 ± 1.4
20 17.5 ± 0.9 20.9 ± 0.1
21 79.9 ± 5.7 51.9 ± 0.3
22 14.5 ± 1.1 10.2 ± 0.5
23 9.3 ± 0.7 9.9 ± 0.5
24 94.8 ± 7.9 >100
25a >100 >100
26 >100 >100
Miltefosine 5.9 ± 1.4 2.4 ± 0.2
AMBdc 0.8 ± 0.1 0.3 ± 0.0
a Complete structure of this compound. SIs: Selectivity Index (splenocytes); SIh: Selecti
SI:  10, and IC50:  1 mM) are bolded for comparison purposes.Mandal et al., 2015), none of the compounds assayed attained the
leishmanicidal potency of AMBdc (EC50: 0.3 mM), which is currently
the most potent reference drug in these assays.
To provide a uniform basis for comparison in these studies, we
assayed all the compounds listed in Tables 1e4 against mouse
spleen macrophages ea primary non-tumoral culture, that repre-
sents the benchmark for comparative screening of antileishmanial
drug candidatese and on HepG2 hepatocytes, a human model for
studies of liver drug toxicity. Although most compounds were less
toxic for human hepatocytes, only two out from those 16 tested
were fairly more potent against Leishmania amastigotes thant the C9’-side chain R. Antileishmanial effects (EC50 ± SD) on promastigotes and
± SD) on murine splenocytes and human HepG2 hepatocytes. Inhibition effects
CC50 (mM) CC50 (mM) IC50 (mM)
otes Murine Splenocytes SIS Human HepG2 SIh Leishmania tubulin
>100 > 10.8 >100 >10.8 2.0 ± 0.3
>100 >3.3 >100 >3.3 0.7 ± 0.0
98.2 ± 10.2 un nt un 1.7 ± 0.1
46.8 ± 7.0 2.6 68.9 ± 6.0 3.8 7.0 ± 0.7
>100 > 23.4 10.4 ± 0.8 2.4 0.9 ± 0.1
42.0 ± 1.9 0.7 73.5 ± 11.6 1.3 >20
21.0 ± 2.3 1.0 45.5 ± 5.6 2.2 4.3 ± 0.4
34.1 ± 3.5 0.7 18.5 ± 0.7 0.4 2.0 ± 0.0
51.3 ± 3.0 5.0 89.9 ± 4.0 8.8 3.1 ± 0.2
>100 > 10.0 >100 >10.0 0.8 ± 0.0
>100 un 14.3 ± 1.2 un >20
>100 un >100 un >20
80.1 ± 4.9 <0.80 27.2 ± 2.2 0.27 >20
64.7 ± 7.0 26.9 50.4 ± 4.3 21 nt
>20 > 62.5 nt un nt
vity Index (HepG2); nt: not tested; un: undefined. Significant values (EC50: 10 mM,
Table 3
Structures and bioactivity results for podophyllic aldehyde derivatives withmodifications at position C-9. Antileishmanial effects (EC50 ± SD) on promastigotes and amastigote-













Comp. R EC50 (mM) CC50 (mM) CC50 (mM) IC50 (mM)
L. infantum promastigotes L. infantum amastigotes Murine Splenocytes SIS Human HepG2 SIh Leishmania tubulin
27 38.3 ± 3.7 31.7 ± 2.1 >100 >6.3 6.6 ± 0.4 0.2 12.1 ± 0.8
28 24.5 ± 1.5 24.5 ± 1.5 >100 >4.1 >100 >4.1 2.9 ± 0.3
29 61.3 ± 0.7 59.4 ± 0.8 >100 >1.7 >100 >1.7 >20
30 19.9 ± 2.1 19.9 ± 2.1 >100 >5.1 nt un 5.6 ± 0.5
31 9.4 ± 0.7 9.4 ± 0.7 >100 >10.1 1.1 ± 0.0 0.1 1.2 ± 0.1
32 14.2 ± 1.8 53.4 ± 4.5 79.3 ± 7.9 1.5 nt un >20
33 41.1 ± 2.4 70.5 ± 3.7 38.7 ± 1.5 0.5 >100 1.4 4.3 ± 0.6
34 94.5 ± 3.0 15.6 ± 0.8 >100 >6.4 1.5 ± 0.1 0.1 0.8 ± 0.0
35 91.0 ± 2.0 67.4 ± 2.0 >100 >1.5 32.4 ± 0.6 0.5 1.6 ± 0.2
36 51.6 ± 1.8 7.5 ± 0.5 58.1 ± 2.7 7.7 nt un 9.0 ± 0.8
37 14.2 ± 2.1 25.3 ± 1.0 8.8 ± 0.5 0.3 >100 >3.9 7.5 ± 1.1
38 >100 >100 >100 un >100 un >20
39 45.2 ± 2.8 24.3 ± 0.5 22.9 ± 0.9 0.9 87.3 ± 6.4 3.6 3.1 ± 0.2
Miltefosine 5.9 ± 1.4 2.4 ± 0.2 64.7 ± 7.0 26.9 50.4 ± 4.3 21.0 nt
AMBdc 0.8 ± 0.1 0.3 ± 0.0 >20 > 62.5 nt un nt
SIS: Selectivity Index (splenocytes), SIh: Selectivity Index (HepG2), nt: not tested, un: undefined. Significant values (EC50: <10 mM, SI: > 10, and IC50: <1 mM) are bolded for
comparison purposes.
J.M. Escudero-Martínez et al. / International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 272e285 277cytotoxic for uninfected splenocytes. The highest selectivity in-
dexes (SIs) for amastigotes were found for podophyllotoxin (2a,
SIs > 7.4) and the isobutyl derivative 5b, which displayed a modest
SIs ¼ 2.7. The remaining compounds had SIs  1.1 (similarly toxicity
for both cell lines or evenmore toxic for the host cell) and therefore,
they were not considered as candidates for further experiments.
The glycolic podolignan 13, though practically inactive against
promastigotes and highly cytotoxic for mouse splenocytes, was the
most potent molecule of this series against amastigotes, and also
turned out to be the most selective with respect to human hepa-
tocytes (SIh > 17.1). These facts suggest the potential interest ofextending the antileishmanial evaluation to other podolignans
containing such a glycolic fragment attached to the C-7 position.
3.2. Activity of podophyllic aldehyde derivatives against L. infantum
In a second instance, the antileishmanial activity of three series
of compounds derived from podophyllic aldehyde (14) was evalu-
ated. This aldehyde was considered as a potential antiparasitic lead
compound, due to its selectivity previously shown against cancer vs
normal cells (Gordaliza et al., 2000). The aldehyde 14 is a cyclo-
lignan resulting from a multi-step chemical process around the
Table 4
Structures and bioactivity results for lignan-heterocycle hybrids with modifications at C-9. Antileishmanial effects (EC50 ± SD) on promastigotes and amastigote-infected













Comp. R1 R2 EC50 (mM) CC50 (mM) CC50 (mM) IC50 (mM)
L. infantum promastigotes L. infantum amastigotes Murine Splenocytes SIS Human HepG2 SIh Leishmania tubulin
40 COOCH3 19.4 ± 2.1 4.5 ± 0.1 >100 > 22.2 8.8 ± 0.3 2.0 1.51 ± 0.0
41 COOCH3 16.3 ± 1.9 9.7 ± 1.8 86.2 ± 0.1 8.9 nt un 16.1 ± 2.1
42 COOCH3 13.9 ± 2.8 12.1 ± 0.4 >100 >8.4 46.8 ± 1.3 3.9 12.1 ± 1.2
43 COOCH3 >100 99.4 ± 6.3 15.6 ± 0.6 0.2 47.5 ± 0.3 0.5 >20
44 COOCH3 >100 42.3 ± 3.1 >100 >2.4 >100 >2.4 >20
45 COOCH2CH3 16.1 ± 2.2 2.5 ± 0.2 71.8 ± 6.0 29.0 nt un >20
46 COOCH3 34.3 ± 1.7 7.3 ± 0.2 >100 > 13.7 51.2 ± 3.6 7.0 0.7 ± 0.0
47 COOCH3 >100 2.2 ± 0.3 >100 > 45.5 9.9 ± 0.6 4.4 >20
48 COOCH3 11.0 ± 0.7 8.9 ± 0.6 71.0 ± 1.5 8.0 65.9 ± 3.3 7.4 1.3 ± 0.0
49 COOCH3 47.0 ± 5.2 21.2 ± 1.1 40.7 ± 6.5 1.9 95.0 ± 14.0 4.5 0.3 ± 0.0
50 COOCH3 >100 43.4 ± 2.1 53.3 ± 3.5 1.2 92.5 ± 6.8 2.1 >20
Miltefosine 5.9 ± 1.4 2.4 ± 0.2 64.7 ± 7.0 26.9 50.4 ± 4.3 21.0 nt
AMBdc 0.8 ± 0.1 0.3 ± 0.0 >20 > 62.5 nt un nt
SIS: Selectivity Index (splenocytes), SIh: Selectivity Index (HepG2), nt: not tested, un: undefined, Significant values (EC50: <10 mM, SI: > 10, and IC50: <1 mM) are bolded for
comparison purposes.
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rupture with C-80 epimerization and C-90 esterification, C7-C8
dehydration and C-9 oxidation), finally leading to the C9-aldehyde
function and the b-axially-oriented carboxylic methyl ester at C-9’.
Many compounds of the first series of podophyllic derivatives
(14e24), retained the aldehyde function at C-9 in order to inves-
tigate the influence of nature and size of the ester chain at position
C-90 upon the antileishmanial activity and cytotoxicities (Table 2).
Additionally, the series includes one compound with the common
trimetoxyphenyl (Ar) fragment extended to a methoxyphthalazine
moiety (25) and a pyrrolidide (26). These are representatives of two
available sub-series of compounds, aiming to detect the respective
and possible influence on the activity by enlarging the polycyclic
structure, and by changing from the ester to an amide function at
position C-9’.
As in the case of podophyllotoxin derivatives, though with the
exceptions of the chloropurine derivative 20 and thepseudodimeric diester 24, the antileishmanial potency of those
active C9’-esters was generally higher (compds. 14, 15, 17e19, 21
and 22) against the amastigote form of the parasite, or similar
(23e26) against both forms. The virtual inactivity observed for the
phthalazine 25 and the pyrrolidide 26 led to preclude further
evaluation of their related sub-series of analogues.
Interestingly, related to the antiparasitic selectivity within this
series (Table 2), the starting lead compound, the aldehyde 14, and
two of its more potent derivatives, the glycolate ester 18 and the
cinnamyl ester 23, displayed significant SIs values of SIs > 10.8,
>23.4 and > 10.0 respectively, although the derivative 18 showed
higher cytotoxicity for HepG2 hepatocytes (SIh ¼ 2.4). On the
contrary, the trimethoxybenzyl ester 22 provided low hepatocyte
toxicity (CC50: 89.9 mM), but less significant SIs values (SIs ¼ 5.0). In
addition, the presence of a terminal olefin, the allyl ester 15
behaved in a similar way (SIs > 3.3). For other compounds of the
series, the actual EC50 values were compromised with their
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The second series of podophyllic aldehyde derivatives (Table 3),
included those compounds resulting from the reaction of the
aldehyde (-CHO) group at position C-9 with a number of amine,
hydrazine and hydroxylamine reagents, thus leading to a diversity
of compounds, including the saturated amine 27, the hydrazone 28,
the oxime 29, the monoimines 30e37, the symmetric azine 38 and
the di-imine 39. The compounds were evaluated on both stages of
L. infantum and, as expected (Table 3), the nature and size of the
imine substituents influenced their leishmanicidal activity. It
should be noted that compounds with the imino C9¼N double
bond may decompose during the assays and, consequently, would
act as pro-drugs of the starting podophyllic aldehyde. This could
particularly happen in the case of in vivo or prolonged in vitro
assaying, due to their possible metabolic or chemical hydrolysis,
with simultaneous liberation of the corresponding amine.
Unlike the majority of molecules so far tested, a moderate but
significant SIs was found for most of compounds belonging of this
series. The most potent compounds of this group in killing
L. infantum amastigotes were the thiazolyl-imine 36
(EC50 ¼ 7.5 mM), and the phenolic-imine 31 (EC50 ¼ 9.4 mM), which
also displayed the highest SIs values (7.7 and > 10.1, respectively).
The remaining compounds had lower potency and more modest
selectivities. It should be also noted the potential hepatotoxicity of
this series of compounds, with the trifluoroethylhydrazone 28, as
the only member showing a SIh value higher than 4. However, some
attention should be paid to the saturated amine 27 (SIs > 6.3),
because despite its discrete leishmanicidal potency
(EC50 ¼ 31.7 mM) and its certain hepatoxicity (SIh ¼ 0.2), it was
unable to destroy murine splenocytes at the maximum concen-
tration tested of 100 mM. This would be chemically supported by
the less reactive character of amines with respect to the unsatu-
rated imines, oximes and hydrazones. This would suggest to extend
the leishmanicidal and cytotoxicity evaluations to other saturated
analogues, with other secondary or tertiary amine functions
attached to C-9. Furthermore, from the chemical and pharmaco-
logical mechanistic points of view, the amines would act by
themselves rather than as pro-drugs, as they are more stable than
those unsaturated derivatives and should need a harder metabolic
processing of oxidative deamination to liberate the precursor
podophyllic aldehyde 14.
Finally, Table 4 shows the structures and antileishmanial results
of the third series of podophyllic aldehyde derivatives 40e50. All
these compounds contain a bicyclic heterocyclic system built on the
aldehyde function and integrating the C-9 carbon atom of the lig-
nan into the heterocyclic fragment. The added fragments were
structurally close to nucleic purine bases, benzoxazole, benzimid-
azole and benzothiazole systems, which are fragments often pre-
sent inmany antiparasitic and antimicrobial agents. In general, as in
the above series, these hybrid compounds were more effective in
killing intracellular amastigotes than against promastigotes of
L. infantum. Interestingly, more than the half of the tested com-
pounds of this series had EC50 values below 20 mM, being the
benzimidazole derivatives 45 (EC50 ¼ 2.5 mM) and 47
(EC50 ¼ 2.2 mM) that presented the highest and similar anti-
leishmanial potencies. The cytotoxicity of these compounds, was
also assayed on murine splenocytes. Most interestingly, these
lignan-benzimidazole/benzoxazole hybrids were revealed as very
selective against amastigote-infected splenocytes, with high values
for the lignan-benzimidazole hybrids 47 (SIs > 45.5), 45 (SIs ¼ 29.0)
and 46 (SIs ¼ > 13.7), and significant values for the lignan-
benzoxazole hybrids 40 (SIs > 22.2), 41 (SIs ¼ 8.9), 42 (SIs > 8.4)
and the dichlorobenzimidazole 48 (SIs ¼ 8.0). Unfortunately, cyto-
toxicities for human HepG2 hepatocytes were not so good and only
the compounds 46 and 48 displayed good SIh values of 7.0 and 7.4,respectively.
3.3. Inhibition of tubulin polymerization
The entire list of compounds was assayed on freshly purified
tubulin obtained from L. infantum promastigotes as described
above (see Fig. S1 A and B from Supplementary Material). Firstly,
the compounds were tested at a single concentration of 20 mM to
discard less potent substances. Then, those active inhibitors of
tubulin polymerization were tested at different concentrations to
determine their IC50 values (results shown in Tables 1e4). Podo-
phyllotoxin (2a) and podophyllic aldehyde (14) were used for
comparison purposes within their respective series 1 and 2e4.
Vinblastine, that inhibits completely tubulin polymerization at
25 mM concentration, was used as positive control in the assay.
As expected, a relevant number of compounds, including
podophyllotoxin (2a) and six podophyllic aldehyde derivatives (15,
18, 23, 34, 46 and 49) showed IC50 values under the mM level, while
other 20 compounds ranged between 1 and 5 mM. The most
effective inhibitors of Leishmania tubulin polymerization were the
lignan-imidazopyridine hybrid 49 (IC50 ¼ 310 nM) and the lignan-
benzimidazole hybrid 46 (IC50 ¼ 660 nM), both in the range of
potency of podophyllotoxin (2a, IC50 ¼ 320 nM) and fairly more
potent than podophyllic aldehyde (14, IC50 ¼ 2.0 mM) (see Fig. S2
from Supplementary Material). Surprisingly, the antileishmanial
and the antitubulin results did not fully correlate. The most potent
anti-tubulin, the imidazopyridine hybrid 49, had resulted less
potent (EC50: 21.2 mM) and fairly less selective (SIs: 1.9) anti-
leishmanial than the above-mentioned benzimidazole (SIs:
8.0e45.5) and benzoxazole (SIs: > 8.4e22.2) hybrids.
3.4. Molecular modelling
The colchicine-binding site lies at the interface between the a
and b subunits of the tubulin heterodimer (Fig. 2A and B). Three
interaction zones in the b subunit (zones 1, 2 and 3) have been
identified in the mammalian model (Massarotti et al., 2012). Both
colchicine and podophyllotoxin interact with amino acids of the a
subunit and with those near the interface of zone 2 in the b het-
erodimer. Amino acids involved in the interaction with colchicine
in the a subunit are fully conserved without any remarkable poly-
morphism in Leishmania. However, several non-synonymous mu-
tations of Leishmania b tubulin may be responsible for the lack of
activity of colchicine in trypanosomatids. Amongst them, 259Met/
259Leu; 316Ala/ 316Ser and 354Ala/ 354Ser (Fig. 2C) are involved in
the interactionwith the trimethoxybenzene fragment of colchicine,
and would be responsible for its difficult conformational arrange-
ment into the binding site. These and other site changes are
responsible for the constrained volume of colchicine binding site in
leishmanial tubulin (from 726.6 Å3 in mammals to 696.0 Å3 in
Leishmania), and should explainwhy colchicine is unable to interact
favorably with its own leishmanial binding site (Fig. 2D and E).
A modelling study of the b subunit of Leishmania tubulin was
conducted on the basis of an interaction complex model of calf
tubulin with podophyllotoxin (PDB:4O2B) [30]. For this purpose,
the co-crystal model of calf tubulin-colchicine complex was used as
template for Leishmania tubulin modelling, using the Auto-
DockTools program. Interactions between podophyllotoxin ana-
logues with calf and Leishmania tubulins were calculated with
AUTODOCK. Apparently, most of the compounds bind tightly to
Leishmania tubulin (Table 5), although some compounds interact
with calf tubulin with higher affinity than with Leishmania tubulin.
This may be due to the actual conformations adopted by different
podolignans in their respective interactions with calf or leishmanial
b-tubulins.
Fig. 2. (A) Ribbon 3D diagram of a and b subunits of L. infantum tubulin dimer. The homology model was generated by superimposition of the structure generated with the a/b-
tubulins from L. infantum (GenBank LinJ.13.0330 and LinJ.08.1280) using the crystallographic structure of the bovine protein with colchicine (PDB:4O2B) as template [30]. (B)
Structural motifs of calf a/b tubulin involved in colchicine binding site. Colchicine (violet) is bound to domains and secondary structure elements of both subunits. In the a-tubulin,
amino acids associated with the T5 loop form part of the pocket-binding site. Elements of b-tubulin are presented and defined as follows: a-helices H7-8, b sheets 8e9 and T7 loop.
(C) Multiple alignment of the peptide sequence of the b subunit of tubulin B. taurus, Saccharomyces cerevisiae, L. infantum and Trypanosoma brucei involved in the colchicine binding
site, showing the pointed polymorphisms in yellow. Representation of a tubulin dimer with the colchicine binding pocket surface in B. taurus (D) and L. infantum (E). (For inter-
pretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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complexes, podophyllotoxin (2a), podophyllic aldehyde (14) and
two derivatives with strong antitubulin effect (46 and 49) were
submitted to a conformational force field optimization imple-
mented by ChemDraw 3D, and docked into leishmanial and calf
tubulins. Fig. 3 (left columns) shows that the docking of podoli-
gnans within the pocket-binding site of Leishmania tubulin can be
different enough (2a, 46, 49) from those found in mammal tubulin
(right column), while other (14) results close similar.
The key interactions between the selected compounds and their
corresponding amino acids in the colchicine-site of Leishmania and
calf tubulins are described in the 2D interaction maps included in
Fig. 4 (See also other 2D maps in Fig. S3, of supplementarymaterial). Most amino acids involved in the interaction of podo-
phyllotoxin with b-tubulin in calf are conserved in the Leishmania
model. However, several changes alter the conformational dispo-
sition of the drug within the pocket-binding site of the parasite
protein. Looking at 2D maps of podophyllotoxin (2a), the change of
259Met / 259Leu in the zone 1 (Fig. 3C) of Leishmania b-tubulin
alters deeply the disposition of the tetracyclic core of podophyllo-
toxin in Leishmania. The dioxole ring of 2a, surrounded by the
amino acids 258Asn in zone 1 and 314Thr and 315Val of zone 2 in calf
tubulin, is exposed to solvent in the Leishmaniamodel due to a 180
rotation of the molecule. However, the trimethoxyphenyl group is
not exposed to solvent in this model due to the 250Ala/250 Ser
change in zone 1 and 316Ala/316Ser change in zone 2. These
Table 5
Tubulin polymerization inhibition, docking energy values and correlative data for








2a 0.32 ± 0.03 9.0 8.0
5a 1.14 ± 0.14 8.9 7.7
14 2.05 ± 0.32 7.5 7.4
15 0.75 ± 0.04 7.9 7.9
21 2.02 ± 0.02 7.4 7.4
23 9.92 ± 0.55 10.2 7.9
31 1.16 ± 0.06 8.4 8.8
34 0.78 ± 0.04 7.8 9.1
35 1.64 ± 0.18 8.5 8.4
40 1.51 ± 0,05 8.3 8.3
46 0.66 ± 0.01 8.4 10.3
48 1.32 ± 0,01 9.8 7.1
49 0.31 ± 0.01 9.2 10.3
Colchicine >100 df 10.3
df: docking failure.
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toxinwith Leishmania b-tubulin in terms of a better docking energy
(9.0 kcal/mol in leishmanial vs 8.0 kcal/mol in mammalian tu-
bulins; Table 5). Looking at the interaction complexes (Fig. 3), 2D
maps (Fig. 4) and docking energies (Table 5) of the hybrid com-
pounds 46 and 49, more important conformational and docking
energy differences can be observed. Obviously, such differences are
due to the bicyclic heterocyclic fragments attached to the lignan
and their bulkier structures, in comparisonwith those in 2a and 14.
Similar studies have been carried out with other compounds
included in Table 5 and graphic results and data can be found in
supplementary files (Fig.S3 and Table S1).4. Discussion
Despite the phylogenetic conservation of a- and b-tubulins,
subtle structural differences in the tubulin-binding site for certain
antitubulin compounds in kinetoplastids have suggested these
proteins as a potential druggable target. Specifically, colchicine is a
potent antimitotic drug that has given rise to lots of new com-
pounds, including podophyllotoxin derivatives and combretastatin
A4 analogues, some of them under clinical trials (Kaur et al., 2014).
From the comparison of 3D models of calf and Leishmania
btubulins, the colchicine-binding site of the b-heterodimer is
specially enriched in amino acid polymorphisms, which reduce the
volume of this binding site in L. infantum (Fig. 2D and E). In addition
to the constrained volume, another reason to explain the lack of
effect of colchicine can be found in the modification of hydropho-
bicity in the binding site. From the 3D model shown in Fig. 2B (and
embedded table) the colchicine-binding site lies between the a and
b subunits. It consists of two S8 and S9 sheets, two H7 and H8
helices connected by the T7 hinge, and the T5 loop at the a-tubulin
subunit. H7 helix contains the 241Cys, which interacts with the
conformationally restricted trimethoxybenzene moiety present in
colchicine and with the more flexible trimethoxyphenyl group of
podophyllotoxin derivatives. According to this model it can be
suggested that the substitution of 259Met from zone 1 (comprised
by T7 loop and H8 helix) of calf b-tubulin by a259Leumay contribute
to the significant displacement of planar R1 pharmacophore (A to D
rings) of podophyllotoxin within the Leishmanial binding pocket.
To this spatial change, the existence of three non-synonymous
mutations within zones 1, 2 and 3 (250Ala/250Ser, 316Ala/316Ser
and 354Ala/354Ser) can generate some hydrophobicity reductionsin several parts of the Leishmania binding pocket. Many of those
amino acids that have been changed should be involved in van der
Waals (Ala)/polar (Ser) interactions with the conformationally rigid
colchicine molecule, and also with combretastatins and podo-
phyllotoxins, through their at least partially rotatable trimethox-
yphenyl ring (ter Haar et al., 1996).
In other sense, the analysis of the effects of podophyllotoxin
derivatives has shown that the hydroxyl group at position C-7awas
essentially needed for the antileishmanial effect. Lack or change of
the substituent at such position and orientation, represented by
deoxypodophyllotoxin (1), the 7-epimer epipodophyllotoxin (2b)
and the keto derivative podophyllotoxone (3), led to ineffective
killers of Leishmania parasites with much lower effects in pre-
venting tubulin polymerization (Lopez-Perez et al., 2004).
Here, we also found that there was no improvement in the
polymerization inhibition of leishmanial tubulin with compounds
having other substituents at positions C-7a or C-7b. This decrease
in activity was previously observed on other cell lines, (Castro et al.,
2003; Lopez-Perez et al., 2004; Abad et al., 2012), and could be due
to additional spatial hindering for the binding to tubulin. However,
relevant exceptions of highly potent polymerization inhibition of
mammalian tubulin were demonstrated for some 7a-alkyl and 7a-
hydroxycycloalkyl derivatives, as for 7a-isopropyl derivative 4 and
for the glycolic pyranyl derivative 13 (Abad et al., 2012) included in
this research (Table 1).
It was also demonstrated that many podophyllic aldehyde de-
rivatives had interesting antileishmanial activity, with SI values
higher than those provided by podophyllotoxin. Modelling of
podophyllic aldehyde (14, Figs. 3 and 4) shows a pattern of inter-
action similar to podophyllotoxin at the colchicine site of leish-
manial tubulin. In this case, the ε-amino group of 254Lys (Fig. 4/14)
in zone 1 of L. infantum b-tubulin is close enough to interact with
the C9-carbonyl group of podophyllic aldehyde, while 247Gln may
interact with the dioxolic ring A. On the other hand, the trime-
thoxyphenyl fragment would undergo some interaction distur-
bances due to the presence of 250Ser, 316Ser and 318Leu in Leishmania
tubulin, with respect to those of 250Ala, 316Ala and 318Ile in bovine
tubulin.
For the series of compounds with the C9-aldehyde group inte-
grated into a bicyclic heterostructure and the b-carboxyester
function at C-9’, we observed that some of them displayed more
potent antileishmanial effects, also with good SI values for infected
splenocytes. In general, these hybrid compounds showed better
results in terms of potency than those from the other series, and
can be compared well with those for glucantime and miltefosine
(Seifert et al., 2003; Mandal et al., 2015), although they were less
effective than AMBdc. Concerning the inhibitory action on leish-
manial tubulin, the hybrid benzoxazole 40, the benzimidazoles 46
and 48 and the imidazopyridine 49 inhibited its polymerization at
low mM levels or even below micromolar concentrations. The
benzoxazole 40 had a strong antitubulin effect (IC50; 1.51 mM) in
parallel with its high antileishmanial potency and selectivity
(SIs > 22.2). However, the dimethylbenzimidazole 47, which dis-
played a higher antileishmanial potency and the highest selectivity
(SIs > 45.5) of all the compounds tested, did not show good
inhibitory activity (IC50 > 20 mM) on tubulin polymerization. It is
worth mentioning here that benzimidazole and benzothiazole
compounds are well-known inhibitors of tubulin polymerization in
nematodes. Several efforts to find correlations between anti-
leishmanial and/or antitubulin effects with docking energies for the
compounds included in Table 5 were unsuccessful. These facts
suggest the probable existence of an alternative mechanism of ac-
tion for a number of compounds that need to be studied and
established through further research.
Fig. 3. Calculated docking of podophyllotoxin (2a), podophyllic aldehyde (14) and the lignan-heterocycle hybrids (46) and (49), as representative bioactive compounds of this
research, in the colchicine site of L. infantum (left panels) and Bos taurus tubulins (right panels). The program used for calculating the figure was AutoDock 4.2 software.
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In summary, we have evaluated and analyzed the anti-
leishmanial effects of 53 podophyllotoxin and podophyllicaldehyde derivatives on both promastigotes and splenocytes
naturally infected with amastigotes of L. infantum. Several dis-
crepancies found between antileishmanial and antitubulin results
displayed by compounds with different but close structures,
Fig. 4. 2D protein ligand interaction maps for compounds 2a (podophyllotoxin), 14 (podophyllic aldehyde), 46 (lignan-benzimidazole hybrid) and 49 (lignan-imidazopyridine
hybrid) on Leishmania (left) and Bos taurus (right) tubulins. Amino acids at a distance lesser than 4 Å are marked as follows: cationic (purple), anionic (red), hydrophobic (green),
polar (blue), and parts exposed to solvent (grey). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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or complementary to the inhibition of tubulin polymerization as
responsible for the antileishmanial effects. This evidence merits
further studies to confirm it and explain how these compounds are
acting on a different therapeutic target, also aiming to progress in
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